Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Fintech (Singapore) Pte. Ltd.

Hutchison China Meditech

13.84
+0.07500.55%
Volume:21.35K
Turnover:293.85K
Market Cap:2.37B
PE:69.18
High:13.89
Open:13.57
Low:13.53
Close:13.76
Loading ...
OverviewCompanyNewsFilings

Company Profile

Company Name:
Hutchison China Meditech
Exchange:
NASDAQ
Establishment Date:
2000
Employees:
1811
Office Location:
Cheung Kong Center,48th floor,2 Queen's Road Central,Hong Kong,Hong Kong
Website:
http://www.hutch-med.com
Zip Code:
- -
Phone:
852 2121 8200
Fax:
852 2128 1778
Introduction:
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.

Directors

Name
Position
Dan ELDAR
Non-executive Director and Chairman
Weiguo SU
Executive Director, Chief Executive Officer and Chief Scientific Officer
Chaohong HU
Independent Non-executive Director
CHENG Chig Fung, Johnny
Executive Director and Chief Financial Officer
Edith SHIH
Non-executive Director and Company Secretary
Graeme Jack
Independent Non-executive Director
Ling YANG
Non-executive Director
MOK Shu Kam, Tony
Senior and Lead Independent Non-executive Director
Paul Rutherford CARTER
Senior Independent Non-executive Director
Renu BHATIA
Independent Non-executive Director
WONG Tak Wai
Independent Non-executive Director

Shareholders

Name
Position
Weiguo SU
Executive Director, Chief Executive Officer and Chief Scientific Officer
CHENG Chig Fung, Johnny
Executive Director and Chief Financial Officer
Mark Lee
Senior Vice President, Corporate Management and Communications
Charles George Rupert NIXON
Group General Counsel
Edith SHIH
Non-executive Director and Company Secretary
May Wang
Executive Vice President, Business Development & Strategic Alliances
Michael Ming SHI
Executive Vice President, Head of R&D and Chief Medical Officer
Zhenping WU
Executive Vice President, Pharmaceutical Sciences and Manufacturing